JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258672

Human SLC22A5 (Solute carrier family 22 member 5) knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

SLC22A5 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 1 bp insertion in exon1.
2 Images
Sanger Sequencing - Human SLC22A5 (Solute carrier family 22 member 5) knockout HeLa cell lysate (AB258672)
  • Sanger seq

Unknown

Sanger Sequencing - Human SLC22A5 (Solute carrier family 22 member 5) knockout HeLa cell lysate (AB258672)

Allele-1 : 1 bp deletion in exon1

Sanger Sequencing - Human SLC22A5 (Solute carrier family 22 member 5) knockout HeLa cell lysate (AB258672)
  • Sanger seq

Unknown

Sanger Sequencing - Human SLC22A5 (Solute carrier family 22 member 5) knockout HeLa cell lysate (AB258672)

Allele-2 : 1 bp insertion in exon1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 1 bp insertion in exon1.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258672-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human SLC22A5 knockout HeLa cell lysate", "number":"AB258672-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB258672-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
SLC22A5
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Solute carrier family 22 member 5 (SLC22A5) also known as OCTN2 is a transporter protein with a molecular mass of approximately 62 kDa. It facilitates the uptake of organic cations and carnitine a type of amino acid derivative into cells. SLC22A5 is expressed widely in tissues with notable presence in skeletal muscle heart kidney intestine and placenta where it plays a significant role in cellular nutrition and detoxification processes.
Biological function summary

SLC22A5 functions to maintain carnitine homeostasis in the body. Carnitine is essential for the transport of long-chain fatty acids into the mitochondria for β-oxidation therefore providing cellular energy. SLC22A5 is a component of the carnitine transport system and interacts directly with other transporters and enzymes involved in the carnitine pathway. It is responsible for mediating the uptake and efflux of L-carnitine and acyl-carnitines across the cell membrane.

Pathways

The involvement of SLC22A5 in fatty acid metabolism is significant. It importantly participates in the carnitine shuttle allowing fatty acids to enter the mitochondria which is integral to energy production via fatty acid β-oxidation. SLC22A5 is linked with the long-chain fatty-acid-CoA ligase proteins which activate fatty acids prior to mitochondrial uptake. The interaction with these proteins ensures efficient energy production in response to cellular demands.

Defective SLC22A5 function is associated with systemic primary carnitine deficiency (CDSP) a disorder characterized by impaired cellular energy metabolism. This deficiency results from a loss of function mutations in the SLC22A5 gene leading to deficient carnitine transport and accumulation of fatty acids in tissues. Additionally SLC22A5 interactions with proteins involved in energy metabolism may play a role in metabolic syndromes as energy imbalance can contribute to the clinical manifestations of these disorders.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com